PF-Atlas › Clinical Trials › NCT01079091

Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units

ADVOS · Not specified

Registry ID

NCT01079091

Phase

Not specified

Status

Terminated

Drug / intervention

ADVOS (Hepa Wash)

Sponsor

Hepa Wash GmbH

Start

2010-09

Enrollment

Locations

About this trial

Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care unit.

View NCT01079091 on ClinicalTrials.gov →

Explore related

All ADVOS trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01079091 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.